Texting Platform for Recurrent UTIs

(Urotrust Trial)

Age: 18+

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: University of Pennsylvania

Must not be taking: Suppressive antibiotics, Immunosuppressive

Disqualifiers: Multidrug resistant UTIs, Interstitial cystitis, Pregnancy, others

No Placebo Group

Approved in 1 Jurisdiction

Trial Summary

What is the purpose of this trial?

The goal of this clinical trial is to compare a texting platform to usual care for managing recurrent urinary tract infections (UTI). The main question it aims to answer is: • can a texting platform that integrates symptom triage and prevention education reduce the rate of unnecessary antibiotics for recurrent UTIs as compared to usual care? Participants enrolled onto the texting platform will: • receive evidence-based clinical guidance for the management of symptoms of UTI and receive educational videos on how to prevent UTIs. An important secondary outcome is to determine if the texting platform improves self-efficacy for the management of recurrent UTI.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but if you are on continuous suppressive antibiotics, you cannot participate.

What data supports the effectiveness of the treatment EHR-integrated rUTI Texting Platform for recurrent UTIs?

The development of the myRUTIcoach eHealth system for women with recurrent UTIs shows that such digital tools can help patients understand preventive strategies, suggesting that a texting platform could similarly aid in managing recurrent UTIs by improving patient knowledge and engagement. ^{1 2 3 4 5}

How is the EHR-integrated rUTI Texting Platform treatment different from other treatments for recurrent UTIs?

The EHR-integrated rUTI Texting Platform is unique because it uses a texting system to help manage recurrent urinary tract infections by integrating with electronic health records (EHR) to provide personalized support and preventive strategies, unlike traditional treatments that primarily focus on medication. ^{1 2 3 6 7}

Eligibility Criteria

This trial is for women over 18 with recurrent UTIs who can give informed consent, follow the study procedures, and have a mobile device that can text. They must be able to read/write English but cannot join if they have urinary system anomalies, certain bladder conditions, recent pregnancy, uncontrolled diabetes or are on specific medications.

Inclusion Criteria

Ability to read and write English

Owns a mobile device with text messaging capability

Provision of signed and dated informed consent form

Exclusion Criteria

I have had cancer in my urinary tract, with or without radiation treatment.

My diabetes is not well-controlled (HbA1c > 9).

I have been using self-catheterization for over a year.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive evidence-based clinical guidance and educational videos for managing recurrent UTIs via a texting platform

12 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• EHR-integrated rUTI Texting Platform (Behavioural Intervention)

Trial Overview Researchers are testing whether an EHR-integrated texting platform offering guidance and education on managing recurrent UTIs improves patients' confidence in handling their condition compared to usual care. The effectiveness will be measured by changes in self-efficacy scores after using the platform.

Participant Groups

Group I: Electronic health record (EHR)-integrated texting platform Experimental Treatment 1 Intervention

Patients will be enrolled into a texting platform for the management of recurrent UTI.

Group II: Usual care Active Control 1 Intervention

Patients will receive usual care through their providers.

Who Is Running the Clinical Trial?

University of Pennsylvania

Lead Sponsor

Trials

2,118

Recruited

45,270,000+

Independence Blue Cross

Collaborator

Trials

7

Recruited

126,000+

Findings from Research

A review of 34 mobile apps for urinary tract infections (UTIs) found that only 11 met the criteria for evaluation, with an average adherence to European Association of Urology (EAU) guidelines of just 31.36%.

Despite high user ratings (average 4.04) and a significant number of downloads, the apps performed poorly in providing effective management strategies for recurrent UTIs, indicating a need for improvement in guideline compliance.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A Content Analysis of Mobile Phone Applications for the Diagnosis, Treatment, and Prevention of Urinary Tract Infections, and Their Compliance with European Association of Urology Guidelines on Urological Infections. Vaggers, S., Puri, P., Wagenlehner, F., et al.[2022]

References

1. England pubmed.ncbi.nlm.nih.gov

Development and feasibility of a telemedicine tool for patients with recurrent urinary tract infection: myRUTIcoach. [2023]

2. New Zealand pubmed.ncbi.nlm.nih.gov

Development of a Prediction Model for Antibiotic-Resistant Urinary Tract Infections Using Integrated Electronic Health Records from Multiple Clinics in North-Central Florida. [2023]

3. Switzerland pubmed.ncbi.nlm.nih.gov

Patients' and Healthcare Professionals' Experiences and Views of Recurrent Urinary Tract Infections in Women: Qualitative Evidence Synthesis and Meta-Ethnography. [2023]

4. United States pubmed.ncbi.nlm.nih.gov

New paradigms in the management of recurrent urinary tract infections. [2021]

5. United States pubmed.ncbi.nlm.nih.gov

Health Education and Symptom Flare Management Using a Video-based m-Health System for Caring Women With IC/BPS. [2019]

6. United States pubmed.ncbi.nlm.nih.gov

An interactive computer kiosk module for the treatment of recurrent uncomplicated cystitis in women. [2019]

7. Netherlands pubmed.ncbi.nlm.nih.gov

A Content Analysis of Mobile Phone Applications for the Diagnosis, Treatment, and Prevention of Urinary Tract Infections, and Their Compliance with European Association of Urology Guidelines on Urological Infections. [2022]